The Acetaminophen/Codeine Phosphate combination is commonly used in situations where additional symptomatic support is needed, particularly for pain symptoms that are poorly managed by non-opioid options. These combinations are primarily intended for the treatment of acute, moderate pain in situations where short-term symptomatic assistance is appropriate.

This medication is applied across therapeutic domains involving heightened symptom expression, which includes addressing pain following minor surgical procedures, acute dental work, and moderate post-traumatic discomfort. Its use is relevant for easing symptoms that interfere with daily comfort, and supports patients during episodes of heightened discomfort. The combination helps address groups of symptoms that may appear suddenly and may require short-term symptomatic assistance to support general well-being.

“The medication may be part of symptomatic management when the pain experienced is consistently rated as moderate in severity.”

Quick Fact: Relief for Acute Moderate Pain
Primary Use: Symptom management for moderate pain.
Benefit: Contributes to improved comfort during periods of heightened symptoms.
Contexts: Post-operative recovery, acute injury-related discomfort.

Regulatory References

1. European Medicines Agency (EMA) guidance on codeine-containing medicines

The use of Di Antalvic (Acetaminophen/Codeine Phosphate) is governed by official regulatory rules, establishing strict criteria for eligibility. The medicine is permitted primarily for Adults and Adolescents aged 12 years and older, and only when treatment for acute moderate pain cannot be adequately achieved using non-opioid options alone.

Contraindicated Populations

Absolute prohibitions against using this medicine are placed on the following groups:

Category	Exclusion Condition
Pediatric	All children under 12 years of age.
Post-Surgery	Patients under 18 years post-tonsillectomy/adenoidectomy for Obstructive Sleep Apnoea.
Metabolic	Individuals known to be CYP2D6 ultra-rapid metabolisers.
Physiological Status	Women who are breastfeeding.
Organ/Respiratory	Patients with severe hepatic insufficiency or acute respiratory depression.

Restricted and Conditional Use

Use requires caution or restrictions for elderly patients, and individuals with a history of drug or alcohol abuse. Restrictions also apply to patients with mild to moderate hepatic or renal impairment or other conditions such as raised intracranial pressure or certain seizure disorders. The regulatory framework rigorously defines this restricted scope, limiting use to individuals who meet specific criteria for age and physiological health.

The official interaction profile for Di Antalvic is defined by two primary regulatory concerns: metabolic alteration and pharmacodynamic reinforcement. The Codeine component is subject to pharmacokinetic interactions involving the CYP2D6 and CYP3A4 enzyme systems. Co-administration with CYP2D6 inhibitors decreases the conversion of Codeine to its active metabolite, officially resulting in reduced analgesic efficacy. Conversely, certain CYP3A4 inhibitors may increase Codeine plasma concentrations, potentially increasing or prolonging adverse reactions.

Formal regulatory labeling designates several combinations as restricted or contraindicated. Monoamine Oxidase Inhibitors (MAOIs) must not be taken within 14 days of this medicine. Due to the risk of profound sedation and respiratory depression, the consumption of alcohol and the co-administration of other CNS depressants (such as benzodiazepines, sedatives, or other opioids) is restricted. Pharmacodynamic interactions also extend to Serotonergic Drugs, which carry a documented risk of Serotonin Syndrome.

The Acetaminophen component presents a separate interaction with oral anticoagulants, such as Warfarin, where co-administration may officially increase anticoagulant effects. Furthermore, official labeling identifies a population-specific constraint: use is contraindicated in CYP2D6 Ultra-Rapid Metabolizers due to the high risk of rapid Morphine conversion and subsequent toxicity. Patients with hepatic or renal impairment may also exhibit slower clearance, heightening general interaction risk.

Dual Central Mechanism: Signal Interruption and Pathway Dampening

The physiological action of Di Antalvic is executed through two distinct, central-acting components that engage in a synergistic mechanism. One component (Codeine) is a prodrug that is converted by the CYP2D6 enzyme into morphine, a mu-Opioid Receptor (mu-OR) agonist. The second component (Acetaminophen) acts primarily as an inhibitor of Cyclooxygenase (COX) enzyme activity within the CNS. This combined approach targets nociceptive signaling at distinct molecular points.

mu-Opioid Receptor Agonism and Neural Blockade

Activation of the mu-OR on neurons in the spinal cord and brainstem triggers a molecular cascade that leads to the hyperpolarization of the nerve cells. This physiological change causes an inhibition of excitatory neurotransmitter release, effectively inhibiting the ascending transmission of nociceptive signals toward cortical regions.

Modulation of Central Chemical Mediators

The acetaminophen component modifies the chemical environment within the CNS. It reduces the synthesis of Prostaglandin E2 ( PGE2) by inhibiting the COX enzyme system. PGE2 is a mediator that sensitizes the central nervous system to nociception. By lowering its concentration, the mechanism reduces the central sensitization induced by nociceptive signals and contributes to the modulation of the hypothalamic thermoregulatory set point.

Pharmacogenetic Constraint on Mechanism Efficacy

The overall functionality of the mechanism is subject to pharmacogenetic constraints, specifically related to the function of the CYP2D6 enzyme. This intrinsic biological limitation results in a physiologically attenuated mu-OR agonism, thereby resulting in attenuated mu-OR-mediated central signal blockade.

How to Use Di Antalvic: Administration Guidelines

Di Antalvic, the trade name for the Acetaminophen/Codeine Phosphate combination, is intended for oral administration as a tablet, capsule, or solution. The product's use is structured by specific dosing limits and schedules to ensure proper application.

---

Usage Protocol

The standard adult regimen involves administering one to two tablets of the combination product per dose. The dosing schedule is defined as as-needed (prn) use, requiring a minimum interval of 4 to 6 hours between successive doses to maintain safe intake.

Administration may occur with or without food. For liquid forms, the procedural rule requires using an accurate milliliter measuring device and shaking suspensions well before measurement to ensure the correct dose is taken.

---

Dosing Constraints and Duration

A critical constraint governing use is the maximum daily limit of the Acetaminophen component: intake from all sources must not exceed 4,000 mg (4 grams) within a 24-hour period. This restriction controls the total number of combination tablets that can be administered in a day. The medication is generally indicated for short-term relief only; its use is not intended for chronic, long-term scheduled maintenance.

Key Administration Parameters
Route of Administration	Oral
Frequency	Every 4 to 6 hours, as needed (prn)
Acetaminophen Daily Max	Not to exceed 4,000 mg (4 grams)

---

Population-Specific Usage

There are specific guidelines for certain age groups. The use of Codeine-containing products is contraindicated in children younger than 12 years of age. For older adults or debilitated patients, a lower starting dose may be considered due to increased sensitivity to analgesic effects.

Research Evidence / Overview of Studies for Di Antalvic (Dextropropoxyphene/Paracetamol)

---

Evidence for Analgesia (Pain Relief)

Research related to Di Antalvic was studied for its use in conditions involving periods of heightened symptoms. The evidence landscape is largely composed of short-term, single-dose Randomized Controlled Trials (RCTs) and systematic reviews that pool the findings from these acute pain studies. These research scenarios typically involve patients who have experienced conditions associated with acute or disruptive episodes of pain, such as pain following dental procedures or minor surgery.

Studies were conducted using a methodology that explored outcomes related to physical discomfort. Researchers primarily measured patient-reported outcomes describing perceived discomfort, focusing on the changes in symptom intensity over short, defined time intervals, usually 4 to 8 hours. The findings describe patterns observed in the studies in these short-term studies, and research highlights changes measured during the study period. Research describes patterns that were observed when the medication was evaluated in controlled, acute settings.

---

Comparing Di Antalvic to Placebo and Other Medications

This part of the section will outline the structure of comparative research. Di Antalvic was observed in studies where it was evaluated in comparison against an inactive substance (placebo) and also against other common analgesics, including single-agent paracetamol and certain non-steroidal anti-inflammatory drugs (NSAIDs). These comparative trials explored short-term symptom changes, focusing on patterns observed when research examined how outcomes related to physical discomfort evolved in these observed populations alongside the use of other agents. Research examined short-term changes as measured in these specific comparative contexts.

---

Long-Term Studies and Follow-up

The majority of high-quality evidence focuses on short-term scenarios, which means long-term effects are not fully established. Research has explored the use of the medication in conditions characterized by functional limitations, such as some types of persistent musculoskeletal pain; however, follow-up durations were limited in these trials. This section details what is known and, more importantly, what remains unclear about the use of the drug over extended periods. The amount of available evidence is small for long-term outcomes, and certainty remains low regarding sustained effects and long-term changes in patient-reported outcomes reflecting daily functioning or activity level. Studies focusing on episodes where symptoms become more noticeable often only monitored responses over defined time intervals.

---

Evidence in Special Populations

The research describing Di Antalvic's measured outcomes for certain groups is limited. The majority of published data describes patterns observed in the general adult population. Specifically, data for certain groups remain insufficient, such as older adults (geriatric populations) and patients with significant comorbidities, which are conditions marked by functional limitations. While the general components of the medication (dextropropoxyphene and paracetamol) was studied for research examining age-related physiological changes, specific, dedicated RCTs for the combination drug in vulnerable or special populations are sparse. This means results apply only to the populations studied, and subgroup findings are uncertain.

---

What is Still Uncertain About Di Antalvic Research

This section synthesizes the main evidence gaps in the research. A primary limitation is that most evidence derives from single-dose, short-duration studies, leaving long-term effects not fully established and outcomes not well characterized. Sample sizes were modest in certain chronic pain studies, and evidence quality varies across studies, leading to heterogeneity. Furthermore, comparative evidence is lacking against several other analgesic alternatives. The research does not determine whether an individual will respond similarly to the group patterns observed, as study results reflect the specific conditions under which they were conducted. Research is ongoing to further examine patient-reported experiences over longer periods of time.

Key Studies & References Dextropropoxyphene: safety and efficacy in older patients (Database of Abstracts of Reviews of Effects - DARE)

Common questions about Di Antalvic (FAQ)

---

Q: Is Di Antalvic still available to buy in some countries?

Official regulatory agencies, such as the EMA and FDA, requested the withdrawal of the older formulation of Di Antalvic (containing dextropropoxyphene/paracetamol) from major markets like the United States, Europe, and Canada. The regulatory status and availability of the medicine under this name or similar combinations may vary in other regions globally.

---

Q: Why did the manufacturer stop selling Di Antalvic in certain regions?

Regulatory agencies, including the EMA and FDA, made the request for withdrawal based on data showing an unfavorable risk-benefit assessment for the historical formulation. The primary concern was the potential for serious cardiac side effects and a narrow therapeutic window, particularly in cases of accidental overdose.

---

Q: Is it true that Di Antalvic was taken off the market because of side effects?

Official regulatory communication states that the historical formulation was assessed by agencies like the FDA and EMA. The decision to remove the product from the market was based on evidence suggesting a risk of serious heart rhythm abnormalities, which led to the conclusion that the benefits did not outweigh the safety risks.

---

Q: Does Di Antalvic cause withdrawal symptoms if you stop taking it suddenly?

Regulatory warnings note that the codeine component can lead to physical dependence when used for prolonged periods. The clinical practice described in official guidelines for long-term users is a gradual reduction in intake to help minimize the possibility of experiencing withdrawal symptoms.

---

Q: Do studies suggest Di Antalvic is effective for long-term chronic pain?

Official documents describe the intended use of this medicine for the short-term relief of acute moderate pain. Research reviews indicate that high-quality evidence regarding the effects and safety of the medicine when used over an extended period for chronic pain is limited, meaning long-term effects are not fully established.

---

Q: Is Di Antalvic known to cause stomach upset or digestive issues?

According to the official safety profile, common adverse effects documented for this combination product include several related to the digestive system. Specifically, regulatory documents list nausea, vomiting, and constipation as frequently observed effects.

---

Q: What kind of research has been done to look at the safety of Di Antalvic?

Drug regulatory agencies mandate that companies conduct extensive safety research, including non-clinical and clinical studies, before a product is approved. Once the drug is on the market, continuous safety monitoring, known as pharmacovigilance, is required to track and evaluate potential risks throughout its use by the population.

---

Q: What happens if someone accidentally takes too much Di Antalvic?

Official warnings emphasize that taking more than the prescribed amount can lead to serious adverse health events. Regulatory documents highlight the severe, life-threatening risks of respiratory depression from the opioid component and liver failure (hepatotoxicity) from the acetaminophen component, defining acute overdose as a medical emergency.

---

Q: Does Di Antalvic show up on standard drug screening tests?

The medicine contains codeine, which is classified as an opioid. According to drug profile information from official sources, the drug and its related metabolites may be detectable in certain types of drug screening protocols that look for opioids.

---

Q: Is there a generic version of the main components in Di Antalvic?

The active ingredients, Acetaminophen and Codeine Phosphate, are a widely recognized combination globally. The formulation is available under its official generic name and numerous other trade names, as recognized by international bodies like the World Health Organization (WHO).

---

Q: Can Di Antalvic be used by older adults (e.g., people over 65)?

Official regulatory documents state that use is permissible for older adults, but note a potential for increased sensitivity to the analgesic effects. Due to this potential, the official guidance suggests that a lower starting dose may be considered in this population group.

---

Q: What are the signs of an allergic reaction to Di Antalvic?

While common side effects are well-documented, official information also describes signs of a serious, rare reaction. These signs, often described in patient leaflets, can include a severe rash, hives, or swelling of the face, tongue, or throat, sometimes accompanied by difficulty breathing.

---

Q: Is it normal to feel a bit light-headed after taking Di Antalvic?

According to the official safety profile for the codeine component, feeling light-headed is a documented common side effect. This effect is often reported alongside other common central nervous system effects, such as dizziness and drowsiness.

---

Q: Has Di Antalvic been studied in children or adolescents?

The use of codeine-containing products is strictly contraindicated by regulatory agencies for all children under 12 years of age. While use is permitted for adolescents aged 12 and older, the overall evidence describing outcomes in this specific age group is described as limited, and criteria must be met.

---

Q: Are there certain recreational drugs that are dangerous to combine with Di Antalvic?

Official warnings note that combining the medicine with any substance that acts as a Central Nervous System (CNS) depressant is restricted. The combination of the medicine with street drugs or other CNS depressants greatly increases the documented risk of severe side effects, including profound sedation, respiratory depression, and potentially coma.

---

Q: Is Di Antalvic recommended for use during pregnancy or while breastfeeding?

Use while breastfeeding is officially contraindicated. For use during pregnancy, official warnings note potential risks to the fetus, including the possibility of the baby experiencing neonatal withdrawal syndrome if exposure occurs near the time of delivery.

---

Q: Has the formula for Di Antalvic changed over time since it was first introduced?

Yes, the name Di Antalvic has historically been associated with two different formulations. The original formula containing dextropropoxyphene/paracetamol was withdrawn by regulatory agencies. The name is also associated with the Acetaminophen/Codeine Phosphate combination, which is the formulation referenced in current monographs.

---

Q: What is the role of the secondary ingredient in Di Antalvic, if it contains one?

The combination contains two active ingredients. Regulatory descriptions explain that they work together in a synergistic action, meaning their total pain relief effect is greater than the sum of their individual effects. This is achieved by managing pain signals through distinct central nervous system pathways.

---

Q: How does the action of Di Antalvic differ from that of a nonsteroidal anti-inflammatory drug (NSAID)?

The medicine's action differs from a standard Nonsteroidal Anti-inflammatory Drug (NSAID) due to its dual mechanism. One component works as an opioid agonist in the brain. The other component (Acetaminophen) primarily works to inhibit certain enzymes in the central nervous system, a process distinct from how many NSAIDs primarily function.

---

Q: Are there any specific genetic factors that influence how a person reacts to Di Antalvic?

Official regulatory labeling addresses genetic factors that can impact how the body processes the medicine. Specifically, individuals who are ultra-rapid metabolizers of codeine, related to the function of the CYP2D6 enzyme, are listed as a contraindicated population due to the heightened risk of toxicity.

---

Q: How long after taking Di Antalvic should I expect to feel relief?

According to official drug profile information, the codeine component typically begins to exert its effects after approximately 30 minutes. The time to reach the maximum pain-relieving effect for the combination is generally noted to occur around two hours after administration.

---

Q: How long does the effect of one dose of Di Antalvic typically last?

The intended duration of action for a single dose is reflected in the official administration guidelines. Regulatory documents state that a minimum interval of 4 to 6 hours is required between successive doses, indicating the general duration of the medicine's effect.

---

Q: Can Di Antalvic affect a person's ability to drive or operate machinery?

Official regulatory documents issue warnings due to common side effects like drowsiness, dizziness, and sedation. These effects are noted as potentially affecting a person's ability to safely drive, operate machinery, or carry out other activities that require full mental alertness and coordination.

---

Q: Does taking Di Antalvic with food change how well it works?

According to official administration guidelines, the medicine may be taken with or without food. This indicates that food consumption does not officially alter the way the medicine works or its overall effectiveness in the body.

---

Q: Is Di Antalvic commonly used for managing pain after surgery?

Research evidence examined by regulatory bodies often includes studies on patients experiencing acute pain following procedures. These studies frequently looked at outcomes in scenarios like pain after dental procedures or minor surgery, which are examples of acute post-operative pain management.

---

Q: Are there any common foods or supplements that might interact with Di Antalvic?

Official regulatory information identifies several substances that may interact with the medicine. Interactions have been noted with substances such as alcohol, grapefruit juice, and St. John’s wort, all of which can increase the risk of certain side effects or alter the medicine's effectiveness.

Official Storage Requirements

Di Antalvic, as an opioid-containing analgesic, must be stored according to strict regulatory guidelines to maintain product quality and prevent misuse. Store the tablets at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), and ensure the container is tight to protect the contents from moisture. Do not freeze the medication. Due to the risk of accidental overdose, the product must be stored securely and kept out of the sight and reach of children at all times.

Disposal of Unused Medicine

Official disposal instructions require unused or expired tablets to be discarded through a medicine take-back program when available. If a take-back program is unavailable, the product must be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed container before being thrown in the household trash. Do not flush the medication down the toilet.